CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 425 filers reported holding CRISPR THERAPEUTICS AG in Q2 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $14,331,392 | +50.0% | 265,347 | +89.3% | 0.00% | 0.0% |
| Q1 2024 | $9,555,827 | -29.6% | 140,197 | -35.3% | 0.00% | 0.0% |
| Q4 2023 | $13,566,672 | +53.2% | 216,720 | +11.1% | 0.00% | 0.0% |
| Q3 2023 | $8,853,092 | -24.4% | 195,045 | -6.4% | 0.00% | -33.3% |
| Q2 2023 | $11,704,348 | -16.1% | 208,485 | -32.4% | 0.00% | 0.0% |
| Q1 2023 | $13,951,374 | -48.3% | 308,454 | -53.5% | 0.00% | -57.1% |
| Q4 2022 | $26,988,876 | +38339.1% | 663,933 | -38.2% | 0.01% | -58.8% |
| Q3 2022 | $70,212 | +80.9% | 1,074,406 | +68.2% | 0.02% | +70.0% |
| Q2 2022 | $38,814 | -99.5% | 638,706 | +447.8% | 0.01% | +400.0% |
| Q1 2022 | $7,319,000 | -58.8% | 116,597 | -50.2% | 0.00% | -33.3% |
| Q4 2021 | $17,746,000 | -51.7% | 234,186 | -28.6% | 0.00% | -62.5% |
| Q3 2021 | $36,722,000 | +195.8% | 328,082 | +327.9% | 0.01% | +166.7% |
| Q2 2021 | $12,414,000 | -10.3% | 76,681 | -32.5% | 0.00% | 0.0% |
| Q1 2021 | $13,838,000 | -27.8% | 113,573 | -9.3% | 0.00% | -40.0% |
| Q4 2020 | $19,168,000 | +197.9% | 125,190 | +62.7% | 0.01% | +150.0% |
| Q3 2020 | $6,434,000 | -20.5% | 76,927 | -30.1% | 0.00% | 0.0% |
| Q2 2020 | $8,088,000 | +82.7% | 110,058 | +5.4% | 0.00% | 0.0% |
| Q1 2020 | $4,428,000 | -55.7% | 104,401 | -36.4% | 0.00% | 0.0% |
| Q4 2019 | $10,005,000 | +335.6% | 164,262 | +193.2% | 0.00% | +100.0% |
| Q3 2019 | $2,297,000 | -4.1% | 56,028 | +10.2% | 0.00% | 0.0% |
| Q2 2019 | $2,396,000 | +61.8% | 50,853 | +22.6% | 0.00% | – |
| Q1 2019 | $1,481,000 | +0.3% | 41,465 | -19.8% | 0.00% | – |
| Q4 2018 | $1,476,000 | -34.3% | 51,679 | +2.0% | 0.00% | -100.0% |
| Q3 2018 | $2,246,000 | -28.7% | 50,650 | -5.5% | 0.00% | 0.0% |
| Q2 2018 | $3,148,000 | +149.8% | 53,578 | +94.4% | 0.00% | – |
| Q1 2018 | $1,260,000 | +136.8% | 27,562 | +21.6% | 0.00% | – |
| Q4 2017 | $532,000 | – | 22,672 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $37,781,000 | 20.21% |
| Ariose Capital Management Ltd | 37,900 | $2,872,000 | 6.78% |
| EcoR1 Capital, LLC | 1,077,483 | $81,652,000 | 2.60% |
| NEA Management Company, LLC | 1,590,002 | $120,490,000 | 2.44% |
| ARK Investment Management | 9,087,868 | $688,679,000 | 2.08% |
| NIA IMPACT ADVISORS, LLC | 62,609 | $3,876,000 | 2.06% |
| Deuterium Capital Management, LLC | 18,000 | $1,364,000 | 2.02% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,200 | $8,192,000 | 1.82% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,789,000 | 1.76% |
| Nikko Asset Management Americas, Inc. | 4,319,471 | $330,526,000 | 1.74% |